Gregory Francis William Gocal Sells 2,000 Shares of Cibus, Inc. (NASDAQ:CBUS) Stock

Cibus, Inc. (NASDAQ:CBUS) EVP Gregory Francis William Gocal sold 2,000 shares of the stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $10.00, for a total transaction of $20,000.00. Following the sale, the executive vice president now owns 318,844 shares in the company, valued at approximately $3,188,440. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Gregory Francis William Gocal also recently made the following trade(s):

• On Monday, July 15th, Gregory Francis William Gocal sold 2,000 shares of Cibus stock. The stock was sold at an average price of $10.01, for a total value of $20,020.00.
• On Friday, July 12th, Gregory Francis William Gocal sold 2,000 shares of Cibus stock. The shares were sold at an average price of $10.00, for a total value of $20,000.00.

Cibus Price Performance

CBUS stock opened at $10.23 on Thursday. The stock has a market cap of $220.46 million, a price-to-earnings ratio of -0.56 and a beta of 1.91. The company has a 50 day simple moving average of $12.08 and a 200 day simple moving average of $16.04. Cibus, Inc. has a 1 year low of $7.41 and a 1 year high of $24.61.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($1.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.01) by ($0.11). Cibus had a negative return on equity of 23.33% and a negative net margin of 12,313.28%. The company had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. During the same quarter last year, the company posted ($5.45) earnings per share. On average, equities research analysts anticipate that Cibus, Inc. will post -3.22 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Cibus in a research note on Friday, May 10th.

Institutional Trading of Cibus

A number of hedge funds have recently made changes to their positions in the company. Citigroup Inc. acquired a new position in shares of Cibus in the third quarter valued at approximately $199,000. Blue Trust Inc. bought a new position in shares of Cibus during the fourth quarter valued at $301,000. Indie Asset Partners LLC lifted its holdings in shares of Cibus by 30.1% during the fourth quarter. Indie Asset Partners LLC now owns 16,929 shares of the company’s stock worth $332,000 after purchasing an additional 3,921 shares during the period. Cerity Partners LLC bought a new stake in shares of Cibus in the fourth quarter worth $323,000. Finally, Gladius Capital Management LP acquired a new stake in Cibus in the fourth quarter valued at $56,000. 33.81% of the stock is owned by institutional investors and hedge funds.

Cibus Company Profile

Cibus, Inc, a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases.